Omalizumab

Red

Brand Name(s):Xolair

Indication:Asthma (severe persistent allergic) in children aged 6 to 11 years

Rationale:1,2,8

Considered:Nov-10

Review Date:Jun-23

Comments:
NICE recommends omalizumab as possible additional treatment to standard asthma therapy for some people aged 6 years and over with severe persistent allergic asthma (see below).

Technology appraisals, TA278 – Issued: April 2013